Results 81 to 90 of about 40,760 (162)

Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study. [PDF]

Front Med (Lausanne)
Zhao H, Meng W, Lv X, Si S, Wu S, Li J, Cai Z, Jin R, Yang L, Li C, Song L.   +10 more
europepmc   +1 more source

Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service. [PDF]

Clin Transl Sci
Libiad Y, Franck B, Tron C, Lalanne S, Boglione-Kerrien C, Taïeb F, Verdier MC, Lemaitre F.   +7 more
europepmc   +1 more source

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes. [PDF]

Sci Rep
Zhu Z, Chen Q, Wang Z, Chen Q, Li X, Liu Y, Lu H, Feng J, Xie M, Dong X, Chen B, Huang J, Zeng X, Zeng Z, Yuan Y, Xu F, Liao X, Liang B, Chen W.   +18 more
europepmc   +1 more source

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. [PDF]

Front Cell Infect Microbiol
Zhang Y, Yang X, Sun L, Zhang R, Fan W, Lin N, Lin B.   +6 more
europepmc   +1 more source

Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. [PDF]

J Am Heart Assoc
Wong CK, So BY, Leung IS, Choo A, Chiu HAC, Tam FC, Lin M, Kwok WC, Lam SC, Chan KE, Un KC, Lam TH, Chu WM, Tam AR, Hung FN, Lip GYH, Tse HF.   +16 more
europepmc   +1 more source

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study. [PDF]

BMC Infect Dis
Edwards LJ, Scaria A, Cheng AC, Amin J, Robinson EJ, Sumpton C, Liu B.   +6 more
europepmc   +1 more source

Viral kinetics in adults with Covid-19 treated with nirmatrelvir-ritonavir or molnupiravir: a population-based, observational cohort study. [PDF]

Virol J
Prager M, Ensle D, Eser H, Glötzl F, Riedl B, Szell M, Valipour A, Zoufaly A, Wenisch C, Haider D, Burgmann H, Thalhammer F, Götzinger F, Jilma B, Karnthaler U, Zeitlinger M, Jorda A.   +16 more
europepmc   +1 more source

Effects of Ritonavir, Lopinavir, and Alcohol on ABC Transporters and Secretion of Bile Acid and Bilirubin in Senescent Hepatocytes. [PDF]

Int J Mol Sci
Chen L, Duran E, Headrick D, Ji C.
europepmc   +1 more source